Until recently, patients diagnosed with locally advanced and metastatic endometrial cancer faced significant challenges in their treatment due to limited options and poor prognostic outcomes. The sequencing of tumors has been a major advancement in its management. It has led to The Cancer Genome Atlas classification currently used in clinical practice and the initiation of several clinical trials for innovative treatments targeting principally signaling pathways, immune checkpoints, DNA integrity, growth factors, hormonal signaling, and metabolism. Numerous clinical trials are investigating a combinatorial approach of these targeted therapies to counter tumoral resistance, cellular compensatory mechanisms, and tumor polyclonality. This review provides a comprehensive overview of historical, current, and promising therapies in advanced and metastatic endometrial cancer. It particularly highlights clinical research on targeted and hormonal therapies, but also immunotherapy, reflecting the evolving landscape of treatment modalities for this disease.
Keyphrases
- endometrial cancer
- squamous cell carcinoma
- locally advanced
- clinical trial
- small cell lung cancer
- single cell
- end stage renal disease
- clinical practice
- neoadjuvant chemotherapy
- cancer therapy
- chronic kidney disease
- ejection fraction
- machine learning
- prognostic factors
- polycystic ovary syndrome
- type diabetes
- phase ii study
- drug delivery
- papillary thyroid
- epithelial mesenchymal transition
- dna methylation
- cell proliferation
- adipose tissue
- lymph node
- weight loss
- patient reported outcomes